$TBIO News
Last published 11mo ago
- 11mo agoTBIOTranslate Bio, Inc. - Appeal, Affirmed-in-PartUS Patent Trial and Appeal Board
- 11mo agoTBIOTranslate Bio, Inc. - Appeal, ReversedUS Patent Trial and Appeal Board
- 2y agoTBIOTelesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA SynthesisGlobeNewswireSAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable
- 2y agoTBIOTelesis Bio Plans to Delist its Securities from The Nasdaq Stock MarketGlobeNewswireSAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO) ("Telesis" or the "Company"), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through
- 2y agoTBIOTelesis Bio Reports Second Quarter and First Half 2024 Financial ResultsGlobeNewswireSAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid
- 2y agoKRONMACKMXCTPHVS+4Vicore Expands and Strengthens its Board of DirectorsACCESS NewswireSTOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of
- 2y agoTBIOTelesis Bio Reports First Quarter 2024 Financial ResultsGlobeNewswireSAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid
- 2y agoTBIOTelesis Bio Announces Reverse Stock SplitGlobeNewswireSAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible,
- 2y agoTBIOTelesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadershipGlobeNewswireSAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the commercial availability
- 2y agoTBIOTelesis Bio Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireSAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid
- 2y agoTBIOTelesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial ResultsGlobeNewswireSAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible and rapid
- 2y agoTBIOTelesis Bio Reports Third Quarter 2023 Financial ResultsGlobeNewswireSAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. "This
- 3y agoTBIOTelesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023GlobeNewswireSAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on
- 3y agoTBIOTelesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNAGlobeNewswireSAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® De novo Cloning
- 3y agoTBIOTelesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGSGlobeNewswireSAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® NGS Library Prep
- 3y agoTBIOTelesis Bio, Inc. (TBIO) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoTBIOTelesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023GlobeNewswireSAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 financial results
- 3y agoTBIOTelesis Bio to Present at Jefferies Healthcare Conference 2023GlobeNewswireSAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will
- 3y agoTBIOTelesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023GlobeNewswireSAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their automated workflow solutions
- 3y agoTBIOTelesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common StockGlobeNewswireSAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the closing of its
- 3y agoTBIOTelesis Bio Secures Financing of $28.0 MillionGlobeNewswireUp to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC with participation from Northpond Ventures, M-185 Corporation and BroadOak Capital Partners SAN DIEGO, May 31, 2023
- 3y agoTBIOTelesis Bio to Present at SynBioBeta 2023GlobeNewswireSAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their benchtop automation solutions
- 3y agoTBIOTelesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning KitGlobeNewswireSAN DIEGO, May 22, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the first commercial shipment of its BioXp® Select DNA
- 3y agoTBIOTelesis Bio Announces First Commercial Shipment of BioXp® NGS Library Prep KitGlobeNewswireSAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the first commercial shipment of its BioXp® NGS Library
- 3y agoTBIOTelesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)GlobeNewswireSAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their benchtop automation solutions
- 3y agoTBIOTelesis Bio Reports First Quarter 2023 Financial ResultsGlobeNewswire-- Total revenue of $6.3M in 1QFY23 -- BioXp® franchise revenue increased by 28% SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology
- 3y agoTBIOTelesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023GlobeNewswireSAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 financial results
- 3y agoTBIOTelesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-upGlobeNewswireSAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced continued expansion of the BioXp® Select Kit product
- 3y agoTBIOTelesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 GuidanceGlobeNewswire-- Record revenue of $9.5M in 4QFY22; Increase of 208% over 4QFY21 -- BioXp® Revenue increased by 158% to $3.4M, in 4QFY22 over 4QFY21 SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc.
- 3y agoTBIOTelesis Bio to Present at Festival of Biologics ConferenceGlobeNewswireSAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced Daniel Gibson, Ph.D., CTO and Co-founder of Telesis Bio
- 3y agoTBIOTelesis Bio to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 21, 2023GlobeNewswireSAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter and full year 2022
- 3y agoTBIOTelesis Bio Releases BioXp® Select mRNA Synthesis Kit to Expand the Utility, Speed, and Impact of Its Automated Synthetic Biology WorkstationGlobeNewswireSAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the availability of its BioXp® Select mRNA Synthesis
- 3y agoDNAYTBIOTelesis Bio Pre-Announces Preliminary Fourth Quarter Financial ResultsGlobeNewswire-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer leveraging
- 4y agoTBIOCystic Fibrosis Pipeline Offers Promising New Options for Treatment | DelveInsightGlobeNewswireLas Vegas, USA, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cystic Fibrosis Pipeline Offers Promising New Options for Treatment | DelveInsight The Cystic Fibrosis (CF) therapeutic development pipeline contains candidate drugs that address many different aspec
- 5y agoRCKTTBIOTRILFrazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public FundBusiness WireFrazier Healthcare Partners announced today the closing of Frazier Life Sciences Public Fund, L.P., exceeding its target and closing on nearly $830 million in capital commitments in an oversubscribed fundraise. Led by Managing Partner Albert Cha, Gen
- 5y agoFLACISEEKRYSRCKT+4Frazier Healthcare Partners Announces Several Promotions on Life Sciences TeamBusiness WireFrazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabra
- 5y agoTBIOTranslate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threate
- 5y agoTBIOTPGSVPCBYSACMoore Kuehn Encourages TPGS, VPCB, YSAC, and TBIO Investors to Contact Law FirmPR NewswireNEW YORK, Aug. 17, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shar
- 5y agoTBIOTranslate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswire-- Entered into a definitive agreement under which Sanofi will acquire, subject to customary conditions to closing, all outstanding shares of Translate Bio with a goal of advancing deployment of mRNA technology across vaccines and therapeutics developme
- 5y agoDISTBIONYTPFE+1Delta Strain Pushes Herd Immunity Threshold Higher: Virus UpdateBloomberg
- 5y agoIGTOTLKTBIOUA+1Thinking about buying stock in Outlook Therapeutics, Translate Bio, International Game Technology, Exela Technologies, or Under Armour?PR NewswireNEW YORK, Aug. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OTLK, TBIO, IGT, XELA, and UA. To se
- 5y agoUAATBIOSAN-FRPFE+11Stocks making the biggest moves in the premarket: Under Armour, Translate Bio, Clorox and moreCNBCThe stocks making the biggest moves in premarket trading include Under Armour, Translate Bio, Clorox, and more.
- 5y agoTBIOSanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics developmentGlobeNewswireSanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast trac
- 5y agoTBIOSanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics DevelopmentGlobeNewswire-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi's recently announced mRNA Center of Excellence -- -- Full integration upgrades dr
- 5y agoDISLLYTBIOPFE+1Biden Tells Governors of Florida, Texas to Lead: Virus UpdateBloomberg
- 5y agoTBIOTranslate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threaten
- 5y agoTBIOSanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza VaccineGlobeNewswire-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data for mRNA influenza vaccine candidates support initi
- 5y agoTBIOTRANSLATE BIO, INC. - Appeal, ReversedUS Patent Trial and Appeal Board
- 5y agoTBIOTranslate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLEXINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Translate Bio (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threaten
- 5y agoTBIOTranslate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine ProgramGlobeNewswire-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to begin in the coming weeks -- LEXINGTON, Mass.,